Exact Sciences (STU:EXK) Total Liabilities : €2,984 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences Total Liabilities?

Exact Sciences's Total Liabilities for the quarter that ended in Mar. 2024 was €2,984 Mil.

Exact Sciences's quarterly Total Liabilities declined from Sep. 2023 (€3,091.73 Mil) to Dec. 2023 (€3,049.97 Mil) and declined from Dec. 2023 (€3,049.97 Mil) to Mar. 2024 (€2,984.21 Mil).

Exact Sciences's annual Total Liabilities increased from Dec. 2021 (€2,918.06 Mil) to Dec. 2022 (€3,005.42 Mil) and increased from Dec. 2022 (€3,005.42 Mil) to Dec. 2023 (€3,049.97 Mil).

Exact Sciences Total Liabilities Historical Data

The historical data trend for Exact Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Total Liabilities Chart

Exact Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,095.94

2,210.80

2,918.06

3,005.42

3,049.97

Exact Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															3,032.34	3,044.92	3,091.73	3,049.97	2,984.21

Exact Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Exact Sciences's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	471.981	+	(2269.892	+	308.096
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3,050

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	5934.213	-	2884.245
	=	3,050

Exact Sciences's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	630.3	+	(2050.873	+	303.034
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2,984

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	5866.215	-	2882.009
	=	2,984

Exact Sciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Sciences (STU:EXK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » Total Liabilities

Comparable Companies

QGEN CRL MEDP NTRA RVTY RDNT SHC GH NEOG DGX TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

EXAS:USA

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.